Oral phentolamine: An alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction

International Journal of Impotence Research

Volumn 12, Issue , 2000, Pages S75-S80

  Goldstein, I ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha blocker; Erectile dysfunction; Oral agents; Penile erection

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; PHENTOLAMINE MESYLATE;

ARTICLE; CATECHOLAMINE RELEASE; CLINICAL TRIAL; CORPUS CAVERNOSUM; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINITIS;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; CLINICAL TRIALS, PHASE III; HUMANS; IMPOTENCE; KINETICS; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PENIS; PHENTOLAMINE;

EID: 0034016716     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900502     Document Type: Article

References (9)

1. Lue TF, Tanagho EA. Physiology of erection and pharmacologic management of impotence. J Urol 1987; 137: 829-836.
2. Brindley GS Cavernosal alpha-blockade: A new technique for investigating and treating erectile impotence. Br J Psychiatry 1983; 143: 332-337.
3. Muller J. JAMA 1996; 275: 1405-1409.
4. Traish A, Gupta S, Gallant C, Huang YH, Goldstein, I. Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms. Int J Imp Res 1998; 10: 215-223.
5. Goldstein I, the Vasomax Study Group: Update of Safety and Efficacy of Oral Phentolamine (Vasomax) in Patients with Erectile dysfnction. Int J Imp Res 1999; 11 (Supple 1): S71.
6. Wyllie M G, Andersson K-E. Oraly Active Agents: The Potential of Alpha-adrenergic Antagonists. In: Carson C, Kirby R, Goldstein, I. eds, Textbook of Erectile Dysfunction. ISIS Medical Media: Oxford 1999; pp. 317-322.
7. Goldstein I, Lue T, Padma-Nathan H, Rosen R, Steers W and Wicker P. Oral sildenafil in the treatment of erectile dysfunction. New EnglJMed 1998; 338: 1397-1404.
8. Lal S, et al. Apomorphine-induced penile tumescence in impotent patients- preliminary findings. Prog Neuropsycho- pharmacol Biol Psychiatr. 1987; 11: 235-242.
9. Goldstein I, Payton T, Schechter, P.J. Double-blind, Placebo- controlled Study of Topiglan, a Topical Gel Formulation of 1% Alprostadil for the In-office Treatment of Erectile Dysfunction. Int J Imp Res 1999; 11 (Supple 1): S71.